Read by QxMD icon Read

Movement Disorders Clinical Practice

Silje Bjerknes, Mathias Toft, Ane E Konglund, Uyen Pham, Trine Rygvold Waage, Lena Pedersen, Mona Skjelland, Ira Haraldsen, Stein Andersson, Espen Dietrichs, Inger Marie Skogseid
Background: Subthalamic nucleus deep brain stimulation improves motor symptoms and fluctuations in advanced Parkinson's disease, but the degree of clinical improvement depends on accurate anatomical electrode placement. Methods used to localize the sensory-motor part of the nucleus vary substantially. Using microelectrode recordings, at least three inserted microelectrodes are needed to obtain a three-dimensional map. Therefore, multiple simultaneously inserted microelectrodes should provide better guidance than single sequential microelectrodes...
May 2018: Movement Disorders Clinical Practice
Joseph Jankovic, Daniel Truong, Atul T Patel, Allison Brashear, Marian Evatt, Roman G Rubio, Chad K Oh, Daniel Snyder, Gill Shears, Cynthia Comella
Background: Injectable daxibotulinumtoxinA (an investigational botulinum toxin, RT002) may offer a more prolonged duration of response-and therefore less frequent dosing-than onabotulinumtoxinA. Objectives: To perform a phase 2, open-label, dose-escalation study to assess the efficacy and safety of daxibotulinumtoxinA in cervical dystonia. Methods: Subjects with moderate-to-severe isolated cervical dystonia were enrolled in sequential cohorts to receive a single open-label, intramuscular dose of injectable daxibotulinumtoxinA of up to 200 U ( n = 12), 200-300 U ( n = 12), or 300-450 U ( n = 13; https://clinicaltrials...
May 2018: Movement Disorders Clinical Practice
Cecília N Prudente, Lena Zetterberg, Annika Bring, Lynley Bradnam, Teresa J Kimberley
Background: Rehabilitation interventions are rarely utilized as an alternative or adjunct therapy for focal dystonias. Reasons for limited utilization are unknown, but lack of conclusive evidence of effectiveness is likely a crucial factor. Methods and Findings: The purpose of this systematic review was to determine the level of evidence for rehabilitation interventions in focal dystonias. Rehabilitation interventions were classified based upon the underlying theoretical basis of different approaches, and the strength of evidence for each category was evaluated to identify gaps in the field...
May 2018: Movement Disorders Clinical Practice
Bettina Balint, Sarah Wiethoff, Davide Martino, Claudia Del Gamba, Anna Latorre, Christos Ganos, Henry Houlden, Kailash P Bhatia
Background: Paroxysmal kinesigenic dyskinesia (PKD) is a rare disorder characterised by brief attacks of chorea, dystonia, or mixed forms precipitated by sudden movement. Methods: Observational study with a cohort of 14 PKD patients and genetic testing for PRRT2 mutations. Results: In a series of 14 PKD patients seen in our clinic at the National Hospital of Neurology, Queen Square, from 2012-2017, we noted tics in 11 patients (79%), which stand in stark contrast to the estimated lifetime prevalence of tics estimated to reach 1%...
May 2018: Movement Disorders Clinical Practice
Jennifer L Whitwell
Background: Positron emission tomography ligands are now available that bind to tau proteins in the brain, providing the exciting opportunity to assess the presence and distribution of tau in vivo in living patients. Methods: This manuscript performed a systematic review of studies that have performed tau PET imaging in patients with parkinsonian disorders. Pubmed was searched up to November 2017, and the review included case reports and patient-control studies...
March 2018: Movement Disorders Clinical Practice
Claire Halsband, Antonia Zapf, Friederike Sixel-Döring, Claudia Trenkwalder, Brit Mollenhauer
Background: Rapid eye movement (REM) sleep behavior disorder (RBD) is one of the most specific prodromal indicators for Parkinson's disease (PD). Objectives: To test the validity of the RBD-Screening Questionnaire (RBDSQ) in assessing RBD in early PD. Methods: The RBDSQ was completed before video-supported polysomnography (vPSG) by 134 de novo PD patients, 109 matched controls without neurological disorder (CTR) and 30 subjects with idiopathic RBD (iRBD) without clinical signs of PD; results were compared with vPSG-confirmed RBD diagnosis...
March 2018: Movement Disorders Clinical Practice
Darius Ebrahimi-Fakhari, Clara Hildebrandt, Peter E Davis, Lance H Rodan, Irina Anselm, Olaf Bodamer
Background: Movement disorders are a significant clinical problem in lysosomal storage diseases (LSD) and account for substantial morbidity. The spectrum of movement disorders in childhood-onset LSD, however, remains poorly defined. Objectives: To define the spectrum of movement disorders in a well-characterized cohort of children with LSD. Methods: A retrospective chart review at a single tertiary care center (Boston Children's Hospital, Boston, MA, USA)...
March 2018: Movement Disorders Clinical Practice
Stuart H Isaacson, Stanley Fahn, Rajesh Pahwa, Caroline M Tanner, Alberto J Espay, Claudia Trenkwalder, Charles H Adler, Rajiv Patni, Reed Johnson
Background: ADS-5102 (amantadine) extended release capsules (GOCOVRI™) are a treatment for dyskinesia in patients with Parkinson's disease (PD). ADS-5102 reduced dyskinesia and OFF time in phase 3 controlled trials of up to six months. Amantadine immediate release (IR) is used for dyskinesia, but suboptimal durability and tolerability limit its clinical utility. Methods: In an ongoing, open-label, phase 3 study in the US and Western Europe (NCT02202551), patients with PD received 274 mg of ADS-5102 (equivalent to 340 mg amantadine HCl) once daily at bedtime for up to two years...
March 2018: Movement Disorders Clinical Practice
Ali Shoeibi, Irene Litvan
No abstract text is available yet for this article.
January 2018: Movement Disorders Clinical Practice
Jared Thomas Hinkle, Kate Perepezko, Catherine C Bakker, Martinus P G Broen, Kathleen Chin, Ted M Dawson, Vanessa Johnson, Zoltan Mari, Cherie L Marvel, Kelly A Mills, Alexander Pantelyat, Olga Pletnikova, Liana S Rosenthal, Melissa D Shepard, Daniel A Stevens, Juan C Troncoso, Jiangxia Wang, Gregory M Pontone
Background: Psychosis is among the most disabling complications of Parkinson's disease (PD). The chronicity of PD psychosis remains understudied and the relative importance of dopaminergic therapy versus the disease process itself in engendering psychosis remains unclear. Objectives: To examine pharmacologic and motoric correlates of PD psychosis onset and remission in a longitudinally monitored PD cohort. Methods: We analyzed data from 165 participants enrolled in a longitudinal PD study through the Morris K...
January 2018: Movement Disorders Clinical Practice
Samantha K Holden, Taylor Finseth, Stefan H Sillau, Brian D Berman
Background: The Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UDPRS) is a commonly used tool to measure Parkinson disease (PD) progression. Longitudinal changes in MDS-UPDRS scores in de novo PD have not been established. Objective: Determine progression rates of MDS-UPDRS scores in de novo PD. Methods: 362 participants from the Parkinson's Progression Markers Initiative, a multicenter longitudinal cohort study of de novo PD, were included...
January 2018: Movement Disorders Clinical Practice
Sana Aslam, Nan Zhang, Charles H Adler, John N Caviness, Erika Driver-Dunckley, Shyamal H Mehta, Marwan N Sabbagh, Christine Belden, Edward Zamrini, Thomas G Beach, Holly A Shill
Introduction: Depression and neuropsychiatric disorders in individuals with essential tremor (ET) are not well characterized in the literature. Methods: We compared 104 ET subjects with 481 non-ET controls involved in the Arizona Study of Aging and Neurodegenerative Disorders. An analysis of baseline depression scales and neuropsychiatric inventory (NPI) was done between the two groups. Comparisons were made additionally within the ET group based on tremor severity, duration of tremor and age of onset...
November 2017: Movement Disorders Clinical Practice
Melanie Wilke, Peter Dechent, Mathias Bähr
View Supplementary Video.
November 2017: Movement Disorders Clinical Practice
David G Standaert, Ramon L Rodriguez, John T Slevin, Michael Lobatz, Susan Eaton, Krai Chatamra, Maurizio F Facheris, Coleen Hall, Kavita Sail, Yash J Jalundhwala, Janet Benesh
Background: Levodopa-carbidopa intestinal gel (LCIG; carbidopa-levodopa enteral suspension in the United States), delivered via percutaneous gastrojejunostomy (PEG-J) and titrated in the inpatient setting, is an established treatment option for advanced Parkinson's disease (PD) patients with motor fluctuations. However, long-term prospective data on the efficacy of LCIG on non-motor symptoms and the safety of outpatient titration are limited. Methods: In this 60-week, open-label phase 3b study, LCIG titration was initiated in an outpatient setting following PEG-J placement in PD patients...
November 2017: Movement Disorders Clinical Practice
Nicolaas I Bohnen, Jacob Haugen, Andrew Ridder, Vikas Kotagal, Roger L Albin, Kirk A Frey, Martijn L T M Müller
Background: Visual function deficits are more common in imbalance-predominant compared to tremor-predominant PD suggesting a pathophysiological role of impaired visual functions in axial motor impairments. Objective: To investigate the relationship between changes in color discrimination and motor impairments in PD while accounting for cognitive or other confounder factors. Methods: PD subjects (n=49, age 66.7±8.3 years; Hoehn & Yahr stage 2...
November 2017: Movement Disorders Clinical Practice
Aasef G Shaikh, Stewart A Factor, Jorge Juncos
Background and objectives: Slowed and curved rapid eye movements, saccades, are the well-known features of progressive supranuclear palsy (PSP). We hypothesized that the saccades in PSP are not only slow and curved, but they are also irregular and have timing deficits. Methods: We tested this hypothesis in 12 patients with PSP by measuring vertical and horizontal visually guided saccades using a limbus tracker. Results: Both, horizontal and vertical saccades were slow and had irregular trajectory and velocity profiles, but deficits were much more robust in vertical saccades...
September 2017: Movement Disorders Clinical Practice
Antonella Conte, Gina Ferrazzano, Giovanni Defazio, Giovanni Fabbrini, Mark Hallett, Alfredo Berardelli
OBJECTIVE: The aim of this five-year longitudinal study was to investigate whether patients with increased blinking develop orbicularis oculi muscle spasms. METHODS: Eleven patients who initially manifested increased blinking alone were clinically and neurophysiologically re-evaluated five years later. RESULTS: By the five-year follow-up assessment, nine of the 11 patients had developed orbicularis oculi muscle spasms. The blink reflex recovery cycle became abnormal whereas somatosensory temporal discrimination, already abnormal at the first evaluation, did not significantly change...
September 2017: Movement Disorders Clinical Practice
Sara M Schaefer, Mark Hallett, Barbara P Karp, Daniel B DiCapua, Sule Tinaz
BACKGROUND: Positional tremors arise when a patient's tremor is brought on during specific positioning of the involved body part. They can be distinguished from postural tremor, wherein a patient's tremor is elicited in any posture, and from task-specific tremor, wherein a patient's tremor occurs only during a certain task. CASES: We describe two cases of positional tremor that are markedly improved with botulinum toxin injection. DISCUSSION: The term "positional" is a valuable descriptor for tremors...
September 2017: Movement Disorders Clinical Practice
Kelsey A Holiday, Eva Pirogovsky-Turk, Vanessa L Malcarne, J Vincent Filoteo, Irene Litvan, Stephanie L Lessig, David Song, Dawn M Schiehser
BACKGROUND: Visual Hallucinations (VH) are a common symptom experienced by individuals with Parkinson's disease (PD); however, a validated measure of VH has yet to be established for this population. The North-East Visual Hallucinations Interview (NEVHI), a promising VH measure, has not been well validated in PD. The aim of this study was to evaluate the convergent and discriminant validity of the NEVHI as well as the proportional identification and characteristics of VH in PD. METHODS: One hundred seventeen individuals with PD completed the NEVHI as well as evaluations of psychological, cognitive, motor, and visual functioning as measures of convergent and divergent validity...
September 2017: Movement Disorders Clinical Practice
Miriam Sklerov, Un Jung Kang, Christopher Liong, Lorraine Clark, Karen Marder, Michael Pauciulo, William C Nichols, Wendy K Chung, Lawrence S Honig, Etty Cortes, Jean Paul Vonsattel, Roy N Alcalay
BACKGROUND: Multiple system atrophy (MSA) is marked by abnormal inclusions of alpha-synuclein in oligodendrogliocytes. Etiology remains unknown. Variants in the glucocerebrosidase gene have been associated with other synucleinopathies, dementia with Lewy bodies and Parkinson disease. It is unclear whether glucocerebrosidase variants are associated with MSA. OBJECTIVES: To analyze the frequency of glucocerebrosidase gene variants among autopsy-proven cases of MSA at a brain bank in New York City...
July 2017: Movement Disorders Clinical Practice
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"